Antidepressant Market in the US 2015-2019

米国の抗うつ剤市場2015-2019

◆タイトル:Antidepressant Market in the US 2015-2019
◆商品コード:IRTNTR5038
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年1月28日
◆ページ数:104
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:米国
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、米国の抗うつ剤市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、米国の抗うつ剤市場規模及び予測、作用機序別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Depression
According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor concentration, as stated by the WHO. Depression can roughly be categorized into six different types. A patient with severe depression can have suicidal thoughts or behaviors. According to a 2012 WHO estimate, approximately 3,000 suicides take place each day, resulting in more than a million deaths per annum. Depression can be recurrent, and can be severely debilitating for an individual. In patients with mild depression, the patient can be treated with medications, and in moderate or severe depression, a patient needs both medication and professional psychotherapy in terms of counseling. It has been reported by the WHO in 2008, that depression equally affects men and women, but women have a 50 percent higher tendency to get affected by depression than men. According to the CDC, depression can lead to adverse behavioral traits in an individual such as, alcoholism, smoking, and sleep disturbance. According to the CDC factsheet, one out of every 10 people is affected with depression in the US. Major depressive disorder is among the most debilitating disorders in the US, and affects approximately 14.8 million adults in the country, aged 18 years and above, according to the NIMH in the US.

TechNavio’s analysts forecast the Antidepressant market in the US to grow at a CAGR of [4.08] percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Antidepressant market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of depression. The Antidepressant market in the US is segmented based on the mechanism of action of the drugs used to treat depression, as illustrated below:

• Tricyclic Antidepressants
• Serotonin Norepinephrine Reuptake Inhibitors
• Selective Serotonin Reuptake Inhibitors
• Monoamine Oxidase Inhibitors
• Others

The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the Antidepressant market in the US. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio’s report, Antidepressant Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the landscape of the Antidepressant market in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Vendors]
• Actavis
• Eli Lilly and Company
• GlaxoSmithKline
• Otsuka Pharmaceutical
• Pfizer

[Other Prominent Vendors]
• Abbott Laboratories
• AstraZeneca
• Aurobindo Pharma
• Bristol-Myers Squibb
• Dr. Reddy’s Laboratories
• H. Lundbeck
• Janssen Pharmaceuticals
• Lupin
• Novartis
• Pierre Fabre
• Shire
• Somerset Pharmaceuticals
• Sun Pharmaceutical
• Sunovion Pharmaceuticals
• Takeda Pharmaceutical
• Teva Pharmaceutical
• Torrent Pharmaceuticals
• Valeant Pharmaceuticals

[Market Driver]
• Rise in Patient Population
• For a full, detailed list, view our report

[Market Challenge]
• Threat from Patent Expiries
• For a full, detailed list, view our report

[Market Trend]
• Growing Public Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Celexa
04.1.2 Fetzima
04.1.3 Lexapro
04.1.4 Viibryd
04.1.5 Cymbalta
04.1.6 Prozac
04.1.7 Symbyax
04.1.8 Paxil
04.1.9 Wellbutrin
04.1.10 Abilify
04.1.11 Effexor
04.1.12 Pristiq
04.1.13 Zoloft

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disorder Overview
07.1 Depression & its Types
07.1.1 Major Depressive Disorder
07.1.2 Persistent Depressive Disorder
07.1.3 Psychotic Depression
07.1.4 Post-partum Depression
07.1.5 Seasonal Affective Disorder
07.1.6 Bipolar Disorder
07.2 Etiology
07.3 Epidemiology
07.3.1 Bipolar Disorder Among Adults
07.3.2 Dysthymic Disorder Among Adults
07.3.3 Major Depression Among Adults
07.3.4 Major Depression Among Adolescents
07.4 Treatment & Management
07.5 Economic Burden

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Mechanism of Action

10.Buying Criteria

11.Market Growth Drivers

12.Drivers and their Impact

13.Market Challenges

14.Impact of Drivers and Challenges

15.Market Trends

16.Trends and their Impact

17.Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Competitive Assessment of the Top Drugs for Depression
17.2.2 Eli Lilly
17.2.3 Otsuka Pharmaceutical
17.2.4 Pfizer
17.2.5 GlaxoSmithKline
17.2.6 Actavis
17.3 Other Prominent Vendors

18.Key Vendor Analysis
18.1 Actavis
18.1.1 Key Facts
18.1.2 Business Description
18.1.3 Business Segmentation
18.1.4 Business Segmentation by Revenue 2012 and 2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Information
18.1.8 SWOT Analysis
18.2 Eli Lilly
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation by Revenue
18.2.4 Sales by Geography
18.2.5 Business Strategy
18.2.6 Key Information
18.2.7 SWOT Analysis
18.3 GlaxoSmithKline
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Sales by Geography
18.3.6 Pipeline Products
18.3.7 Business Strategy
18.3.8 Key Information
18.3.9 SWOT Analysis
18.4 Otsuka Pharmaceutical
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2014
18.4.4 Business Segmentation by Revenue 2013 and 2014
18.4.5 Geographical Segmentation by Revenue 2014
18.4.6 Business Strategy
18.4.7 Recent Developments
18.4.8 SWOT Analysis
18.5 Pfizer
18.5.1 Key Facts
18.5.2 Business Overview
18.5.3 Business Segmentation by Revenue 2013
18.5.4 Business Segmentation by Revenue 2012 and 2013
18.5.5 Geographical Segmentation by Revenue
18.5.6 Business Strategy
18.5.7 Key Developments
18.5.8 SWOT Analysis

19.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: NIMH Classification of Depression
Exhibit 3: Prevalence Data for Major Depressive Disorder Episodes in US Adults (2012)
Exhibit 4: Prevalence Data for Dysthymic Disorder Episodes in US Adults (2012)
Exhibit 5: Prevalence Data for Major Depressive Disorder Episodes according to the Severe Impairment Episodes in US Adults (2012)
Exhibit 6: Prevalence Data for Major Depressive Disorder Episodes in US Adults (2012)
Exhibit 7: Prevalence Data for Major Depression Among Adults in US (2012)
Exhibit 8: Management of Depression According to the WHO Guidelines
Exhibit 9: Economic Burden of Depression in the US
Exhibit 10: A Break-up of the Costs Associated with Depression
Exhibit 11: Snapshot of the Economic Burden of Depression in the US
Exhibit 12: Antidepressant Market in the US 2014-2019 (US$ million)
Exhibit 13: Drivers and Challenges of the Antidepressant Market in the US
Exhibit 14: Antidepressant Market in the US Segmentation by Mechanism of Action
Exhibit 15: Antidepressants Market in the US Segmentation by Mechanism of Action
Exhibit 16: Buying Criteria of the Antidepressant Market in the US
Exhibit 17: Drivers and their Impact on the Key Customer Category of the Antidepressant Market in the US
Exhibit 18: Antidepressant Market in the US Market Share Analysis 2014
Exhibit 19: Revenue Comparison of Top Drugs for Depression in 2013 (US$ million)
Exhibit 20: YoY Revenue of Cymbalta in the US 2010-2013 (US$ million)
Exhibit 21: YoY Global Revenue of Cymbalta 2010-2013 (US$ million)
Exhibit 22: YoY Revenue of Abilify (in the US, the UK, Germany, Spain, France, Italy and some other European countries) 2010-2013 (US$ million)
Exhibit 23: YoY Global Revenue of Pristiq 2010-2013 (US$ million)
Exhibit 24: YoY Global Revenue of Zoloft 2010-2013 (US$ million)
Exhibit 25: YoY Global Revenue of Effexor 2010-2013 (US$ million)
Exhibit 26: YoY Revenue of Wellbutrin in the US 2010-2013 (US$ million)
Exhibit 27: YoY Global Revenue of Wellbutrin 2010-2013 (US$ million)
Exhibit 28: YoY Global Revenue of Paxil 2010-2014 (US$ million)
Exhibit 29: Actavis: Business Segmentation 2013
Exhibit 30: Actavis: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 31: Actavis : Sales by Geography (in US$ million)
Exhibit 32: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 33: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 34: Eli Lilly: Sales by Geography 2013
Exhibit 35: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 36: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 37: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 38: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 39: Otsuka Pharmaceutical: Business Segmentation by Revenue 2014
Exhibit 40: Otsuka Pharmaceutical: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 41: Otsuka Pharmaceutical: Geographical Segmentation by Revenue 2014
Exhibit 42: Pfizer: Business Segmentation by Revenue 2013
Exhibit 43: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 44: Pfizer: Geographical Segmentation by Revenue 2013



【掲載企業】

Actavis , Eli Lilly and Company, GlaxoSmithKline , Otsuka Pharmaceutical , Pfizer , Abbott Laboratories, AstraZeneca, Aurobindo Pharma, Bristol-Myers Squibb, Dr. Reddy's Laboratories, H. Lundbeck, Janssen Pharmaceuticals, Lupin, Novartis, Pierre Fabre , Shire , SomersetPharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Valeant Pharmaceuticals

【資料のキーワード】

抗うつ剤、うつ病、治療薬、米国

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[米国の抗うつ剤市場2015-2019] (Antidepressant Market in the US 2015-2019 / IRTNTR5038)販売に関する免責事項
[米国の抗うつ剤市場2015-2019] (Antidepressant Market in the US 2015-2019 / IRTNTR5038)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆